| Abbott says Trilipix results are promising | Posted on 09/06/2009 in Pharmaceutical Company Product News Abbott's results from Trilipix (fenofibric acid) clinical trials are "promising", it has been stated.
The delayed-release capsules are available by prescription and are used to lower triglycerides, as well as LDL cholesterol, while increasing HDL cholesterol.
In examinations it was found to help patients with mixed dyslipidemia and type 2 diabetes achieve lipid targets when taken alongside rosuvastatin calcium.
The combination of the two products resulted in three times more patients reaching the desired HDL, triglycerides and LDL levels, compared to the pre-determined monotherapy.
Dr Robert Rosenson from the State University of New York remarked the data from the investigations has been promising.
"Because diabetes is a risk factor for heart disease, it is particularly important that patients with diabetes and mixed dyslipidemia manage all three key lipid parameters," he explained.
Last week, Abbott announced it had entered a partnership with AstraZeneca to co-promote Trilipix.
Divisional vice-president of the former's primary care department Jeffrey Stewart noted the partnership would help educate physicians about how the drug could benefit their patients.Other news stories from 09/06/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
